Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-986278 in renal impairment and ESRD
NCT06723535Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Dec 2024
- Primary completion
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of admilparant (3 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Maximum Observed Concentration at 8 days, Area Under the Plasma Concentration-Time Curve from Time Zero to Time of Last Quantifiable Concentration at 8 days and 1 more. Started Dec 2024; status: completed.
02
Drugs
admilparant
Beyond the preview
Go deeper on NCT06723535.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06723535.